ResMed Inc. P/E Ratio 2009–2025
ResMed Inc. reported 26.87 of price-to-earnings ratio for fiscal 2025. That was 1.0% lower than fiscal 2024. Compared with fiscal 2020, the change was -37.1%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 26.87 | -1.0% |
| FY 2024 | 27.15 | -22.1% |
| FY 2023 | 34.84 | -8.6% |
| FY 2022 | 38.11 | -47.7% |
| FY 2021 | 72.81 | +70.5% |
| FY 2020 | 42.69 | +4.2% |
| FY 2019 | 40.96 | -6.5% |
| FY 2018 | 43.83 | +48.2% |
| FY 2017 | 29.58 | +30.4% |
| FY 2016 | 22.69 | +13.6% |
| FY 2015 | 19.97 | +9.9% |
| FY 2014 | 18.16 | +0.6% |
| FY 2013 | 18.05 | +19.7% |
| FY 2012 | 15.08 | -15.1% |
| FY 2011 | 17.77 | -13.1% |
| FY 2010 | 20.43 | +15.3% |
| FY 2009 | 17.72 | — |
Source: ResMed Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open RMD 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ResMed Inc. reported 26.87 of price-to-earnings ratio for fiscal 2025. That was 1.0% lower than fiscal 2024. Compared with fiscal 2020, the change was -37.1%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ResMed Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeResMed Inc. — frequently asked questions
What is ResMed Inc.'s price-to-earnings ratio?
ResMed Inc. (RMD) reported price-to-earnings ratio of 26.87 for fiscal year 2025, per its SEC filings.
How has ResMed Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, RMD's price-to-earnings ratio grew at roughly 2.6% per year (compound annual rate), from 17.72 to 26.87.
Where does this data come from?
Figures are computed from ResMed Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More RMD financial history
Full RMD fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →